Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program PR Newswire WALTHAM, Mass., Dec. 10, 2024 -- SIGNAL-AA demonstrated encouraging...
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Nov. 7, 2024 -- Bempikibart Phase 2 topline results in atopic dermatitis (AD) and...
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference PR Newswire WALTHAM, Mass., Nov. 5, 2024 WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB...
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 PR Newswire WALTHAM, Mass., Oct. 14...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.19 | -5.42857142857 | 3.5 | 3.77 | 3.02 | 674434 | 3.35944995 | CS |
4 | -23.54 | -87.6722532588 | 26.85 | 28.66 | 3.02 | 718664 | 6.41316337 | CS |
12 | -41.58 | -92.6264201381 | 44.89 | 53.17 | 3.02 | 294254 | 14.33427752 | CS |
26 | -12.24 | -78.7138263666 | 15.55 | 53.79 | 3.02 | 195093 | 21.11202948 | CS |
52 | -12.93 | -79.618226601 | 16.24 | 53.79 | 3.02 | 147202 | 21.44406893 | CS |
156 | -12.93 | -79.618226601 | 16.24 | 53.79 | 3.02 | 147202 | 21.44406893 | CS |
260 | -12.93 | -79.618226601 | 16.24 | 53.79 | 3.02 | 147202 | 21.44406893 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約